Showing posts with label DISEASE. Show all posts
Showing posts with label DISEASE. Show all posts

Saturday, 14 March 2015

Did you know this about swine flu?

What is the swine flu?

Swine flu (swine influenza) is a respiratory disease caused by viruses (influenza viruses) that infect the respiratory tract of pigs, resulting in nasal secretions, a barking cough, decreased appetite, and listless behavior. Swine flu produces most of the same symptoms in pigs as human flu produces in people. Swine flu can last about one to two weeks in pigs that survive. Swine influenza virus was first isolated from pigs in 1930 in the U.S. and has been recognized by pork producers and veterinarians to cause infections in pigs worldwide. In a number of instances, people have developed the swine flu infection when they are closely associated with pigs (for example, farmers, pork processors), and likewise, pig populations have occasionally been infected with the human flu infection. In most instances, the cross-species infections (swine virus to man; human flu virus to pigs) have remained in local areas and have not caused national or worldwide infections in either pigs or humans. Unfortunately, this cross-species situation with influenza viruses has had the potential to change. Investigators decided the 2009 so-called "swine flu" strain, first seen in Mexico, should be termed novel H1N1 flu since it was mainly found infecting people and exhibits two main surface antigens, H1 (hemagglutinin type 1) and N1 (neuraminidase type1). The eight RNA strands from novel H1N1 flu have one strand derived from human flu strains, two from avian (bird) strains, and five from swine strains.
Swine flu is transmitted from person to person by inhalation or ingestion of droplets containing virus from people sneezing or coughing; it is not transmitted by eating cooked pork products. The newest swine flu virus that has caused swine flu is influenza A H3N2v (commonly termed H3N2v) that began as an outbreak in 2011. The "v" in the name means the virus is a variant that normally infects only pigs but has begun to infect humans. There have been small outbreaks of H1N1 since the pandemic; a recent one is in India where at least three people have died.


Picture of antigenic shift and antigenic drift in swine flu (H1N1).


Swine flu (H1N1 and H3N2v influenza virus) facts


Swine flu is a respiratory disease caused by influenza viruses that infect the respiratory tract of pigs and result in a barking cough, decreased appetite, nasal secretions, and listless behavior; the virus can be transmitted to humans.

Swine flu viruses may mutate (change) so that they are easily transmissible among humans.

The 2009 swine flu outbreak (pandemic) was due to infection with the H1N1 virus and was first observed in Mexico.

Symptoms of swine flu in humans are similar to most influenza infections: fever (100 F or greater), cough, nasal secretions, fatigue, and headache.

Vaccination is the best way to prevent or reduce the chances of becoming infected with influenza viruses.

Two antiviral agents, zanamivir (Relenza) and oseltamivir (Tamiflu), have been reported to help prevent or reduce the effects of swine flu if taken within 48 hours of the onset of symptoms.

There are various methods listed in this article to help individuals from getting the flu.

The most serious complication of the flu is pneumonia.

What causes swine flu? & Why is swine flu now infecting humans?

What causes swine flu?

The cause of the 2009 swine flu was an influenza A virus type designated as H1N1. In 2011, a new swine flu virus was detected. The new strain was named influenza A (H3N2)v. Only a few people (mainly children) were first infected, but officials from the U.S. Centers for Disease Control and Prevention (CDC) reported increased numbers of people infected in the 2012-2013 flu season. Currently, there are not large numbers of people infected with H3N2v. Unfortunately, another virus termed H3N2 (note no "v" in its name) has been detected and caused flu, but this strain is different from H3N2v. In general, all of the influenza A viruses have a structure similar to the H1N1 virus; each type has a somewhat different H and/or N structure.

Why is swine flu now infecting humans?

Many researchers now consider that two main series of events can lead to swine flu (and also avian or bird flu) becoming a major cause for influenza illness in humans.
First, the influenza viruses (types A, B, C) are enveloped RNA viruses with a segmented genome; this means the viral RNA genetic code is not a single strand of RNA but exists as eight different RNA segments in the influenza viruses. A human (or bird) influenza virus can infect a pig respiratory cell at the same time as a swine influenza virus; some of the replicating RNA strands from the human virus can get mistakenly enclosed inside the enveloped swine influenza virus. For example, one cell could contain eight swine flu and eight human flu RNA segments. The total number of RNA types in one cell would be 16; four swine and four human flu RNA segments could be incorporated into one particle, making a viable eight RNA-segmented flu virus from the 16 available segment types. Various combinations of RNA segments can result in a new subtype of virus (this process is known as antigenic shift) that may have the ability to preferentially infect humans but still show characteristics unique to the swine influenza virus (see Figure 1). It is even possible to include RNA strands from birds, swine, and human influenza viruses into one virus if a single cell becomes infected with all three types of influenza (for example, two bird flu, three swine flu, and three human flu RNA segments to produce a viable eight-segment new type of flu viral genome). Formation of a new viral type is considered to be antigenic shift; small changes within an individual RNA segment in flu viruses are termed antigenic drift (see figure 1) and result in minor changes in the virus. However, these small genetic changes can accumulate over time to produce enough minor changes that cumulatively alter the virus' makeup over time (usually years).
Second, pigs can play a unique role as an intermediary host to new flu types because pig respiratory cells can be infected directly with bird, human, and other mammalian flu viruses. Consequently, pig respiratory cells are able to be infected with many types of flu and can function as a "mixing pot" for flu RNA segments (see figure 1). Bird flu viruses, which usually infect the gastrointestinal cells of many bird species, are shed in bird feces. Pigs can pick these viruses up from the environment, and this seems to be the major way that bird flu virus RNA segments enter the mammalian flu virus population. Figure 1 shows this process in H1N1, but the figure represents the genetic process for all flu viruses, including human, swine, and avian strains.

WHAT IS SWINE FLU

What is the swine flu?

Swine flu (swine influenza) is a respiratory disease caused by viruses (influenza viruses) that infect the respiratory tract of pigs, resulting in nasal secretions, a barking cough, decreased appetite, and listless behavior. Swine flu produces most of the same symptoms in pigs as human flu produces in people. Swine flu can last about one to two weeks in pigs that survive. Swine influenza virus was first isolated from pigs in 1930 in the U.S. and has been recognized by pork producers and veterinarians to cause infections in pigs worldwide. In a number of instances, people have developed the swine flu infection when they are closely associated with pigs (for example, farmers, pork processors), and likewise, pig populations have occasionally been infected with the human flu infection. In most instances, the cross-species infections (swine virus to man; human flu virus to pigs) have remained in local areas and have not caused national or worldwide infections in either pigs or humans. Unfortunately, this cross-species situation with influenza viruses has had the potential to change. Investigators decided the 2009 so-called "swine flu" strain, first seen in Mexico, should be termed novel H1N1 flu since it was mainly found infecting people and exhibits two main surface antigens, H1 (hemagglutinin type 1) and N1 (neuraminidase type1). The eight RNA strands from novel H1N1 flu have one strand derived from human flu strains, two from avian (bird) strains, and five from swine strains.

Swine flu is transmitted from person to person by inhalation or ingestion of droplets containing virus from people sneezing or coughing; it is not transmitted by eating cooked pork products. The newest swine flu virus that has caused swine flu is influenza A H3N2v (commonly termed H3N2v) that began as an outbreak in 2011. The "v" in the name means the virus is a variant that normally infects only pigs but has begun to infect humans. There have been small outbreaks of H1N1 since the pandemic; a recent one is in India where at least three people have died.
What is the history of swine flu in humans?

In 1976, there was an outbreak of swine flu at Fort Dix. This virus was not the same as the 2009 H1N1 outbreak, but it was similar insofar as it was an influenza A virus that had similarities to the swine flu virus. There was one death at Fort Dix. The government decided to produce a vaccine against this virus, but the vaccine was associated with rare instances of neurological complications (Guillain-Barré syndrome) and was discontinued. Some individuals speculate that formalin, used to inactivate the virus, may have played a role in the development of this complication in 1976. One of the reasons it takes a few months to develop a new vaccine is to test the vaccine for safety to avoid the complications seen in the 1976 vaccine. Individuals with active infections or diseases of the nervous system are also not recommended to get flu vaccines.

Early in the spring of 2009, H1N1 flu virus was first detected in Mexico, causing some deaths among a "younger" population. It began increasing during the summer 2009 and rapidly spread to the U.S. and to Europe and eventually worldwide. The WHO declared it first fit their criteria for an epidemic and then, in June 2009, the WHO declared the first flu pandemic in 41 years. There was a worldwide concern and people began to improve in hand washing and other prevention methods while they awaited vaccine development. The trivalent vaccine made for the 2009-2010 flu season offered virtually no protection from H1N1. New vaccines were developed (both live and killed virus) and started to become available in Sept. 2009-Oct. 2009. The CDC established a protocol guideline for those who should get the vaccine first. By late December to January, a vaccine against H1N1 was available in moderate supply worldwide. The numbers of infected patients began to recede and the pandemic ended. However, a strain of H1N1 was incorporated into the yearly trivalent vaccine for the 2010-2011 flu season because the virus was present in the world populations.

As stated in the first section of this article, a new strain of swine flu, (H3N2)v, was detected in 2011; it has not affected any large numbers of people in the current flu season. However, another antigenically distinct virus with the same H and N components (termed H3N2 (note no "v") has caused flu in humans; viral antigens were incorporated into the 2013-2014 seasonal flu shots and nasal spray vaccines


Swine influenza, also called pig influenza, swine flu, hog flu and pig flu, is an infection caused by any one of several types of swine influenza viruses. Swine influenza virus (SIV) or swine-origin influenza virus (S-OIV) is any strain of the influenza family of viruses that is endemic in pigs.[2] As of 2009, the known SIV strains include influenza C and the subtypes of influenza A known as H1N1, H1N2, H2N1, H3N1, H3N2, and H2N3.

Swine influenza virus is common throughout pig populations worldwide. Transmission of the virus from pigs to humans is not common and does not always lead to human flu, often resulting only in the production of antibodies in the blood. If transmission does cause human flu, it is called zoonotic swine flu. People with regular exposure to pigs are at increased risk of swine flu infection.

Around the mid-20th century, identification of influenza subtypes became possible, allowing accurate diagnosis of transmission to humans. Since then, only 50 such transmissions have been confirmed. These strains of swine flu rarely pass from human to human. Symptoms of zoonotic swine flu in humans are similar to those of influenza and of influenza-like illness in general, namely chills, fever, sore throat, muscle pains, severe headache, coughing, weakness and general discomfort.

In August 2010, the World Health Organization declared the swine flu pandemic officially over.

Cases of swine flu have been reported in India, with over 25000 positive test cases and 1370 deaths till March 2015.


Tuesday, 16 December 2014

Prion Diseases

A prion (Listeni/ˈpriːɒn/) is an infectious agent, specifically a protein in a misfolded form. The word prion, coined in 1982 by Stanley B. Prusiner, is derived from the words protein and infection. The protein itself, whether in its misfolded or its correctly folded form, can be referred to as the prion protein (PrP). A protein as an infectious agent stands in contrast to all other known infectious agents, like viruses, bacteria, fungi, or parasites—all of which must contain nucleic acids (either DNA, RNA, or both). Prions are responsible for mammalian transmissible spongiform encephalopathies, including bovine spongiform encephalopathy (BSE, also known as "mad cow disease") and scrapie in sheep. In humans, prions cause Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), Gerstmann–Sträussler–Scheinker syndrome, Fatal Familial Insomnia and kuru.[4] All known prion diseases in mammals affect the structure of the brain or other neural tissue and all are currently untreatable and universally fatal. In 2013, a study revealed that 1 in 2,000 people in the United Kingdom might harbour the infectious prion protein that causes vCJD.

Prions are not considered living organisms but are misfolded protein molecules which may propagate by transmitting a misfolded protein state. If a prion enters a healthy organism, it induces existing, properly folded proteins to convert into the disease-associated, misfolded prion form; the prion acts as a template to guide the misfolding of more proteins into prion form. These newly formed prions can then go on to convert more proteins themselves; this triggers a chain reaction that produces large amounts of the prion form. All known prions induce the formation of an amyloid fold, in which the protein polymerises into an aggregate consisting of tightly packed beta sheets. Amyloid aggregates are fibrils, growing at their ends, and replicating when breakage causes two growing ends to become four growing ends. The incubation period of prion diseases is determined by the exponential growth rate associated with prion replication, which is a balance between the linear growth and the breakage of aggregates. (Note that the propagation of the prion depends on the presence of normally folded protein in which the prion can induce misfolding; animals that do not express the normal form of the prion protein can neither develop nor transmit the disease.)

This altered structure is extremely stable and accumulates in infected tissue, causing tissue damage and cell death.[9] This structural stability means that prions are resistant to denaturation by chemical and physical agents, making disposal and containment of these particles difficult. Prions come in different strains, each with a slightly different structure, and, most of the time, strains breed true. Prion replication is nevertheless subject to occasional epimutation and then natural selection just like other forms of replication.

All known mammalian prion diseases are caused by the so-called prion protein, PrP. The endogenous, properly folded form is denoted PrPC (for Common or Cellular), whereas the disease-linked, misfolded form is denoted PrPSc (for Scrapie, after one of the diseases first linked to prions and neurodegeneration.)[11][12] The precise structure of the prion is not known, though they can be formed by combining PrPC, polyadenylic acid, and lipids in a Protein Misfolding Cyclic Amplification (PMCA) reaction. Proteins showing prion-type behavior are also found in some fungi, which has been useful in helping to understand mammalian prions. Fungal prions do not appear to cause disease in their hosts

Saturday, 6 December 2014

Streptococcus pyogenes

Streptococcus pyogenes (Group A streptococcus) is a Gram-positive, nonmotile, nonsporeforming coccus that occurs in chains or in pairs of cells. Individual cells are round-to-ovoid cocci, 0.6-1.0 micrometer in diameter (Figure 1). Streptococci divide in one plane and thus occur in pairs or (especially in liquid media or clinical material) in chains of varying lengths. The metabolism ofS. pyogenes is fermentative; the organism is a catalase-negative aerotolerant anaerobe (facultative anaerobe), and requires enriched medium containing blood in order to grow. Group A streptococci typically have a capsule composed of hyaluronic acid and exhibit beta (clear) hemolysis on blood agar.
 



Figure 1. Streptococcus pyogenes. Left. Gram stain of Streptococcus pyogenes in a clinical specimen. Right. Colonies of Streptococcus pyogenes on blood agar exhibiting beta (clear) hemolysis.
Streptococcus pyogenes is one of the most frequent pathogens of humans. It is estimated that between 5-15% of normal individuals harbor the bacterium, usually in the respiratory tract, without signs of disease. As normal flora, S. pyogenes can infect when defenses are compromised or when the organisms are able to penetrate the constitutive defenses. When the bacteria are introduced or transmitted to vulnerable tissues, a variety of types of suppurative infectionscan occur.
In the last century, infections by S. pyogenes claimed many lives especially since the organism was the most important cause of puerperal fever (sepsis after childbirth). Scarlet fever was formerly a severe complication of streptococcal infection, but now, because of antibiotic therapy, it is little more than streptococcal pharyngitis accompanied by rash. Similarly, erysipelas (a form of cellulitis accompanied by fever and systemic toxicity) is less common today. However, there has been a recent increase in variety, severity andsequelae of Streptococcus pyogenes infections, and a resurgence of severe invasive infections, prompting descriptions of "flesh eating bacteria" in the news media. A complete explanation for the decline and resurgence is not known. Today, the pathogen is of major concern because of the occasional cases of rapidly progressive disease and because of the small risk of serious sequelae in untreated infections. These diseases remain a major worldwide health concern, and effort is being directed toward clarifying the risk and mechanisms of these sequelae and identifying rheumatogenic and nephritogenic strains of streptococci.
Acute Streptococcus pyogenes infections may present as pharyngitis (strep throat), scarlet fever (rash), impetigo (infection of the superficial layers of the skin) or cellulitis (infection of the deep layers of the skin). Invasive, toxigenic infections can result in necrotizing fasciitismyositis and streptococcal toxic shock syndrome. Patients may also develop immune-mediated post-streptococcal sequelae, such as acute rheumatic fever and acuteglomerulonephritis, following acute infections caused by Streptococcus pyogenes.
Streptococcus pyogenes produces a wide array of virulence factors and a very large number of diseases. Virulence factors of Group A streptococci include: (1)M protein, fibronectin-binding protein (Protein F) and lipoteichoic acid for adherence; (2) hyaluronic acid capsule as an immunological disguise and to inhibit phagocytosis; M-protein to inhibit phagocytosis (3) invasins such asstreptokinasestreptodornase (DNase B), hyaluronidase, andstreptolysins; (4) exotoxins, such as pyrogenic (erythrogenic) toxin which causes the rash of scarlet fever and systemic toxic shock syndrome.
Classification of Streptococci

Hemolysis on blood agar

The type of hemolytic reaction displayed on blood agar has long been used to classify the streptococci. Beta -hemolysis is associated with complete lysis of red cells surrounding the colony, whereas alpha-hemolysis is a partial or "green" hemolysis associated with reduction of red cell hemoglobin. Nonhemolytic colonies have been termed gamma-hemolytic. Hemolysis is affected by the species and age of red cells, as well as by other properties of the base medium. Group A streptococci are nearly always beta-hemolytic; related Group B can manifest alpha, beta or gamma hemolysis. Most strains ofS. pneumoniae are alpha-hemolytic but can cause ß-hemolysis during anaerobic incubation. Most of the oral streptococci and enterococci are non hemolytic. The property of hemolysis is not very reliable for the absolute identification of streptococci, but it is widely used in rapid screens for identification of S. pyogenes and S. pneumoniae.
Antigenic types

The cell surface structure of Group A streptococci is among the most studied of any bacteria (Figure 2). The cell wall is composed of repeating units of N-acetylglucosamine and N-acetylmuramic acid, the standard peptidoglycan. Historically, the definitive identification of streptococci has rested on the serologic reactivity of "cell wall" polysaccharide antigens as originally described by Rebecca Lancefield. Eighteen group-specific antigens (Lancefield groups) were established. The Group A polysaccharide is a polymer of N-acetylglucosamine and rhamnose. Some group antigens are shared by more than one species. This polysaccharide is also called the C substance or group carbohydrate antigen



Pathogenesis
Streptococcus pyogenes owes its major success as a pathogen to its ability to colonize and rapidly multiply and spread in its host while evading phagocytosis and confusing the immune system.
Acute diseases associated with Streptococcus pyogenes occur chiefly in therespiratory tractbloodstream, or the skin. Streptococcal disease is most often a respiratory infection (pharyngitis or tonsillitis) or a skin infection (pyoderma). Some strains of streptococci show a predilection for the respiratory tract; others, for the skin. Generally, streptococcal isolates from the pharynx and respiratory tract do not cause skin infections. Figure 3 describes the pathogenesis of S. pyogenes infections.
S. pyogenes is the leading cause of uncomplicated bacterial pharyngitis andtonsillitis commonly referred to a strep throat. Other respiratory infections include sinusitisotitis, and pneumonia.
Infections of the skin can be superficial (impetigo) or deep (cellulitis). Invasive streptococci cause joint or bone infections, destructive wound infections (necrotizing fasciitis) and myositismeningitis andendocarditis. Two post streptococcal sequelaerheumatic fever andglomerulonephritis, may follow streptococcal disease, and occur in 1-3% of untreated infections. These conditions and their pathology are not attributable to dissemination of bacteria, but to aberrent immunological reactions to Group A streptococcal antigens. Scarlet fever and streptococcal toxic shock syndromeare systemic responses to circulating bacterial toxins.
The cell surface of Streptococcus pyogenes accounts for many of the bacterium's determinants of virulence, especially those concerned with colonization and evasion of phagocytosis and the host immune responses. The surface of Streptococcus pyogenes is incredibly complex and chemically-diverse. Antigenic components include capsular polysaccharide (C-substance), cell wall peptidoglycan and lipoteichoic acid (LTA), and a variety of surface proteins, including M proteinfimbrial proteinsfibronectin-binding proteins, (e.g. Protein F) and cell-bound streptokinase.
The cytoplasmic membrane of S. pyogenes contains some antigens similar to those of human cardiac, skeletal, and smooth muscle, heart valve fibroblasts, and neuronal tissues, resulting in molecular mimicry and a tolerant or suppressed immune response by the host.
The cell envelope of a Group A streptococcus is illustrated in Figure 2. The complexity of the surface can be seen in several of the electron micrographs of the bacterium that accompany this article.


Figure 2. Cell surface structure of Streptococcus pyogenes and secreted products involved in virulence.
In Group A streptococci, the R and T proteins are used as epidemiologic markers and have no known role in virulence. The group carbohydrate antigen (composed of  N-acetylglucosamine and rhamnose) has been thought to have no role in virulence, but emerging strains with increased invasive capacity produce a very mucoid colony, suggesting a role of the capsule in virulence.
The M proteins are clearly virulence factors associated with both colonization and resistance to phagocytosis.  More than 50 types of S. pyogenes M proteins have been identified on the basis of antigenic specificity, and it is the M protein that is the major cause of antigenic shift and antigenic drift in the Group A streptococci. The M protein (found in fimbriae) also binds fibrinogen from serum and blocks the binding of complement to the underlying peptidoglycan. This allows survival of the organism by inhibiting phagocytosis.
The streptococcal M protein, as well as peptidoglycan, N-acetylglucosamine, and group-specific carbohydrate, contain antigenic epitopes that mimic those of mammalian muscle and connective tissue. As mentioned above, the cell surface of recently emerging strains of streptococci is distinctly mucoid (indicating that they are highly encapsulated). These strains are also rich in surface M protein. The M proteins of certain M-types are considered rheumatogenic since they contain antigenic epitopes related to heart muscle, and they therefore may lead to autoimmune rheumatic carditis (rheumatic fever) following an acute infection.
The Hyaluronic Acid Capsule
The capsule of S. pyogenes is non antigenic since it is composed of hyaluronic acid, which is chemically similar to that of host connective tissue. This allows the bacterium to hide its own antigens and to go unrecognized as antigenic by its host. The Hyaluronic acid capsule also prevents opsonized phagocytosis by neutrophils or mancrophages.
Adhesins
Colonization of tissues by S. pyogenes is thought to result from a failure in the constitutive defenses (normal flora and other nonspecific defense mechanisms) which allows establishment of the bacterium at a portal of entry (often the upper respiratory tract or the skin) where the organism multiplies and causes an inflammatory purulent lesion.
It is now realized that S. pyogenes (like many other bacterial pathogens) produces multiple adhesins with varied specificities. There is  evidence thatStreptococcus pyogenes utilizes lipoteichoic acids (LTA)M protein, and multiple fibronectin-binding proteins in its repertoire of adhesins. LTA is anchored to proteins on the bacterial surface, including the M protein. Both the M proteins and lipoteichoic acid are supported externally to the cell wall on fimbriae and appear to mediate bacterial adherence to host epithelial cells. The fibronectin-binding protein, Protein F, has also been shown to mediate streptococcal adherence to the amino terminus of fibronectin on mucosal surfaces.
Identification of Streptococcuspyogenes adhesins has long been a subject of conflict and debate. Most of the debate was between proponents of the LTA model and those of the M protein model. In 1972, Gibbons and his colleagues proposed that attachment of streptococci to the oral mucosa of mice is dependent on M protein. However, Olfek and Beachey argued that lipoteichoic acid (LTA), rather than M protein, was responsible for streptococcal adherence to buccal epithelial cells. In 1996, Hasty and Courtney proposed a two-step model of attachment that involved both M protein and teichoic acids. They suggested that LTA loosely tethers streptococci to epithelial cells, and then M protein and/or other fibronectin (Fn)-binding proteins secure a firmer, irreversible association. The first streptococcal fibronectin-binding protein (Sfb) was demonstrated in 1992. Shortly thereafter, protein F was discovered.  Most recently (1998), the M1 and M3 proteins were shown to bind fibronectin.
Extracellular products: invasins and exotoxins
Colonization of the upper respiratory tract and acute pharyngitis may spread to other portions of the upper or lower respiratory tracts resulting in infections of the middle ear (otitis media), sinuses (sinusitis), or lungs (pneumonia). In addition, meningitis can occur by direct extension of infection from the middle ear or sinuses to the meninges or by way of bloodstream invasion from the pulmonary focus. Bacteremia can also result in infection of bones (osteomyelitis) or joints (arthritis). During these aspects of acute disease the streptococci bring into play a variety of secretory proteins that mediate their invasion.
For the most part, streptococcal invasins and protein toxins interact with mammalian blood and tissue components in ways that kill host cells and provoke a damaging inflammatory response. The soluble extracellular growth products and toxins of Streptococcus pyogenes (see Figure 2, above), have been studied intensely. Streptolysin S is an oxygen-stable leukocidin; Streptolysin O is an oxygen-labile leukocidin. NADase is also leukotoxic. Hyaluronidase (the original  "spreading factor") can digest host connective tissue hyaluronic acid, as well as the organism's own capsule. Streptokinases participate in fibrin lysis.Streptodornases A-D possess deoxyribonuclease activity; Streptodornases B and D possess ribonuclease activity as well. Protease activity similar to that inStaphylococcus aureus has been shown in strains causing soft tissue necrosis or toxic shock syndrome. This large repertoire of products is important in the pathogenesis of S. pyogenes infections. Even so, antibodies to these products are relatively insignificant in protection of the host.
The streptococcal invasins act in a variety of ways summarized in Table 1 at the end of this article. Streptococcal invasins lyse eukaryotic cells, including red blood cells and phagocytes; they lyse other host macromolecules, including enzymes and informational molecules; they allow the bacteria to spread among tissues by dissolving host fibrin and intercellular ground substances.
Pyrogenic Exotoxins
Three streptococcal pyrogenic exotoxins (SPE), formerly known asErythrogenic toxin, are recognized: types A, B, C. These toxins act assuperantigens by a mechanism similar to those described for staphylococci. As antigens, they do not requiring processing by antigen presenting cells. Rather, they stimulate T cells by binding class II MHC molecules directly and nonspecifically. With superantigens about 20% of T cells may be stimulated (vs 1/10,000 T cells stimulated by conventional antigens) resulting in massive detrimental cytokine release. SPE A and SPE C are encoded by lysogenic phages; the gene for SPE B is located on the bacterial chromosome.
The erythrogenic toxin is so-named for its association with scarlet fever which occurs when the toxin is disseminated in the blood. Re-emergence in the late 1980's of exotoxin-producing strains of S. pyogenes has been associated with atoxic shock-like syndrome similar in pathogenesis and manifestation to staphylococcal toxic shock syndrome, and with other forms of invasive disease associated with severe tissue destruction. The latter condition is termednecrotizing fasciitis. Outbreaks of sepsis, toxic shock and necrotizing fasciitis have been reported at increasing frequency. The destructive nature of wound infections prompted the popular press to refer to S. pyogenes as "flesh-eating bacteria" and "skin-eating streptococci". The increase in invasive streptococcal disease was associated with emergence of a highly virulent serotype M1 which is disseminated world-wide. The M1 strain produces the erythrogenic toxin (Spe A), thought to be responsible for toxic shock,  and the enzyme  cysteine protease which is involved in tissue destruction. Because clusters of toxic shock were also associated with other serotypes, particularly M3 strains, it is believed that unidentified host factors may also have played an important role in the resurgence of these dangerous infections.


FIGURE 3. Pathogenesis of Streptococcus pyogenes infections. Adapted from Baron's Medical Microbiology Chapter 13, Streptococcus by Maria Jevitz Patterson.

Post streptococcal sequelae

Infection with Streptococcus pyogenes can give rise to serious nonsuppurative sequelae: acute rheumatic fever and acute glomerulonephritis. These pathological events begin 1-3 weeks after an acute streptococcal illness, a latent period consistent with an immune-mediated etiology. Whether all S. pyogenesstrains are rheumatogenic is controversial; however, clearly not all strains are nephritogenic.
Acute rheumatic fever is a sequel only of pharyngeal infections, but acuteglomerulonephritis can follow infections of the pharynx or the skin. Although there is no adequate explanation for the precise pathogenesis of acute rheumatic fever, an abnormal or enhanced immune response seems essential. Also, persistence of the organism on pharyngeal tissues (i.e., the tonsils) is associated with an increased likelihood of rheumatic fever. Acute rheumatic fever can result in permanent damage to the heart valves. Less than 1% of sporadic streptococcal pharyngitis infections result in acute rheumatic fever; however, recurrences are common, and life-long antibiotic prophylaxis is recommended following a single case.
The occurrence of cross-reactive antigens in S. pyogenes and heart tissues possibly explains the autoimmune responses that develop following some infections. The antibody mediated immune (AMI) response (i.e., level of serum antibody) is higher in patients with rheumatic fever than in patients with uncomplicated pharyngitis. In addition, cell-mediated immunity (CMI) seems to play a role in the pathology of acute rheumatic fever.
Acute glomerulonephritis results from deposition of antigen-antibody-complement complexes on the basement membrane of kidney glomeruli. The antigen may be streptococcal in origin or it may be a host tissue species with antigenic determinants similar to those of streptococcal antigen (cross-reactive epitopes for endocardium, sarcolemma, vascular smooth muscle). The incidence of acute glomerulonephritis in the United States is variable, perhaps due to cycling of nephritogenic strains, but it appears to be decreasing. Recurrences are uncommon, and prophylaxis following an initial attack is unnecessary.
Host defenses

S. pyogenes is usually an exogenous secondary invader, following viral disease or disturbances in the normal bacterial flora. In the normal human the skin is an effective barrier against invasive streptococci, and nonspecific defense mechanisms prevent the bacteria from penetrating beyond the superficial epithelium of the upper respiratory tract. These mechanisms include mucociliary movement, coughing, sneezing and epiglottal reflexes.
The host phagocytic system is a second line of defense against streptococcal invasion. Organisms can be opsonized by activation of the classical or alternate complement pathway and by anti-streptococcal antibodies in the serum. S. pyogenes is rapidly killed following phagocytosis enhanced by specific antibody. The bacteria do not produce catalase or significant amounts of superoxide dismutase to inactivate the oxygen metabolites (hydrogen peroxide, superoxide) produced by the oxygen-dependent mechanisms of the phagocyte. Therefore, they are quickly killed after engulfment by phagocytes. The streptococcal defense must be one to stay out of phagocytes.
In immune individuals, IgG antibodies reactive with M protein promote phagocytosis which results in killing of the organism. This is the major mechanism by which AMI is able to terminate Group A streptococcal infections.M protein vaccines are a major candidate for use against rheumatic fever, but certain M protein types cross-react antigenically with the heart and themselves may be responsible for rheumatic carditis. This risk of autoimmunity has prevented the use of Group A streptococcal vaccines. However, since the cross-reactive epitopes of the M-protein  are now known, it appears that limited anti-streptococcal vaccines are on the horizon.


FIGURE 4. Phagocytosis of Streptococcus pyogenes by a macrophage.CELLS alive!
The hyaluronic acid capsule allows the organism to evade opsonization. The capsule is also an antigenic disguise that hides bacterial antigens and is non antigenic to the host. Actually, the hyaluronic acid outer surface of S. pyogenesis weakly antigenic, but it does not result in stimulation of protective immunity. The only protective immunity that results from infection by Group A streptococcus comes from the development of type-specific antibody to the M protein of the fimbriae, which protrude from the cell wall through the capsular structure. This antibody, which follows respiratory and skin infections, is persistent. Presumably, protective levels of specific IgA is produced in the respiratory secretions while protective levels of IgG are formed in the serum. Sometimes, intervention of an infection with effective antibiotic treatment precludes the development of this persistent antibody. This accounts, in part, for recurring infections in an individual by the same streptococcal strain. Antibody to the erythrogenic toxin involved in scarlet fever is also long lasting.
Treatment and prevention

Penicillin is still uniformly effective in treatment of Group A streptococcal disease. It is important to identify and treat Group A streptococcal infections in order to prevent sequelae. No effective vaccine has been produced, but specific M-protein vaccines are being tested.



Table 1. Summary of virulence determinants of Streptococcus pyogenes
Adherence (colonization) surface macromolecules
M protein
Lipoteichoic acid (LTA)
Protein F and Sfb (fibronectin-binding proteins)

Enhancement of spread in tissues
Hyaluronidase hydrolyses hyaluronic acid, part of the ground substance in host tissues.
Proteases
Streptokinase lyses fibrin
Evasion of phagocytosis
Capsule: hyaluronic acid is produced.
C5a peptidase: C5a enhances chemotaxis of phagocytes .
M protein is a fibrillar surface protein. Its distal end bears a negative charge that interferes with phagocytosis. It also blocks complement deposition on the cell surface. Mutations during the course of infection alter the structure of M proteins, rendering some antibodies ineffective. Strains that persist in carriers frequently exhibit altered M proteins.
Leukocidins, including streptolysin S and streptolysin O, are proteins secreted by the streptococci to kill phagocytes (and probably to release nutrients for their growth)
Defense against host immune responses
Antigenic disguise and tolerance provided by hyaluronic acid capsule
Antigenic variation. Antibody against M protein (antigen) is the only effective protective antibody, but there are more than 50 different M types, and subsequent infections may occur with a different M serotype.
Production of toxins and other systemic effects
Toxic shock: Exotoxin is superantigen that binds directly to MHC II (without being processed) and binds abnormally to the T cell receptor of many (up to 20% of) T cells. Exaggerated production of cytokines causes the signs of shock: fever, rash, low blood pressure. aberrant interaction between toxin, macrophage, and T cells.
Induction of circulating, cross-reactive antibodies
Some of the antibodies produced during infection by certain strains of streptococci cross-react with certain host tissues. These antibodies can indirectly damage host tissues, even after the organisms have been cleared, and cause autoimmune complications.



Table 2. Summary of diseases caused by Streptococcus pyogenes
Suppurative conditions (active infections associated with pus) occur in the throat, skin, and systemically.
Throat
Streptococcal pharyngitis is acquired by inhaling aerosols emitted by infected individuals. The symptoms reflect the inflammatory events at the site of infection. A few (1-3%) people develop rheumatic fever weeks after the infection has cleared.
Skin
Impetigo involves the infection of epidermal layers of skin. Pre-pubertal children are the most susceptible. Cellulitis occurs when the infection spreads subcutaneous tissues. Erysipelas is the infection of the dermis. About 5% of patients will develop more disseminated disease. Necrotizing fasciitis involves infection of the fascia and may proceed rapidly to underlying muscle.
Systemic
Scarlet fever is caused by production of erythrogenic toxin by a few strains of the organism.
Toxic shock is caused by a few strains that produce a toxic shock-like toxin.
Non-suppurative Sequelae
Some of the antibodies produced during the above infections cross-react with certain host tissues. These can indirectly damage host tissues, even after the organisms have beencleared, and cause non suppurative complications.
Rheumatic fever. M protein cross reacts with sarcolemma. Antibodies cross-react with heart tissue, fix complement, and cause damage.
Glomerulonephritis. Antigen-antibody complexes may be deposited in kidney, fix complement, and damage glomeruli. Only a few M-types are nephritogenic. 

Gallery of electron micrographs of Streptococcus pyogenes from The Laboratory of Pathogenesis and Immunology at Rockefeller University, the home of research on Streptococcus pyogenes



Critical point dried whole group A streptococci (Streptococcus pyogenes) viewed directly by transmission electron microscopy (TEM 6,500X). Chains of streptococci are clearly evident. To remove cell surface proteins, cells were treated with trypsin prior to preparation and mounting. Strain: D471; M-type 6. Electron micrograph of Streptococcus pyogenes by Maria Fazio and Vincent A. Fischetti, Ph.D. with permission. The Laboratory of Bacterial Pathogenesis and Immunology, Rockefeller University.




Dividing streptococci (12,000X). Electron micrograph of Streptococcus pyogenes by Maria Fazio and Vincent A. Fischetti, Ph.D. with permission.The Laboratory of Bacterial Pathogenesis and Immunology, Rockefeller University.




Electron micrograph of an ultra-thin section of a chain of group A streptococci (20,000X). The cell surface fibrils, consisting primarily of M protein, are clearly evident. The bacterial cell wall, to which the fibrils are attached, is also clearly seen as the light staining region between the fibrils and the dark staining cell interior. Incipient cell division is also indicated by the nascent septum formation (seen as an indentation of the cell wall) near the cell equator. The streptococcal cell diameter is equal to approximately one micron. Electron micrograph of Streptococcus pyogenes by Maria Fazio and Vincent A. Fischetti, Ph.D. with permission.The Laboratory of Bacterial Pathogenesis and Immunology, Rockefeller University.




Negative staining of group A streptococci viewed by TEM 28,000X. The "halo" around the chain of cells (approximately equal in thickness to the cell diameter) is the remnants of the capsule that may be found surrounding the exterior of certain strains of group A streptococci. The septa between pairs of dividing cells may also be seen. Electron micrograph of Streptococcus pyogenes by Maria Fazio and Vincent A. Fischetti, Ph.D. with permission. The Laboratory of Bacterial Pathogenesis and Immunology, Rockefeller University.




High magnification electron micrograph of an ultra-thin section of a group A streptococcus sibling pair (70,000 X). At this magnification, especially in the cell on the left, the cell wall and cell surface fibrils, consisting primarily of M protein, are well defined. Interdigitaion of these fibrils between neighboring cells of different chains is also in plain view. Strain: C126/21/1; M-type 43. Electron micrograph of Streptococcus pyogenes by Maria Fazio and Vincent A. Fischetti, Ph.D. with permission.The Laboratory of Bacterial Pathogenesis and Immunology, Rockefeller University. 


END OF CHAPTER 

Polio Virus Life Cycle


Friday, 5 December 2014

Mechanism for Releasing Enveloped Viruses


Abstract

Many enveloped viruses complete their replication cycle by forming vesicles that bud from the plasma membrane. Some viruses encode “late” (L) domain motifs that are able to hijack host proteins involved in the vacuolar protein sorting (VPS) pathway, a cellular budding process that gives rise to multivesicular bodies and that is topologically equivalent to virus budding. Although many enveloped viruses share this mechanism, examples of viruses that require additional viral factors and viruses that appear to be independent of the VPS pathway have been identified. Alternative mechanisms for virus budding could involve other topologically similar process such as cell abscission, which occurs following cytokinesis, or virus budding could proceed spontaneously as a result of lipid microdomain accumulation of viral proteins. Further examination of novel virus–host protein interactions and characterization of other enveloped viruses for which budding requirements are currently unknown will lead to a better understanding of the cellular processes involved in virus assembly and budding.


Replication Cycle of a Retrovirus





*********DOWNLOAD THIS VEDIO *********

*********DOWNLOAD THIS VEDIO *********
PLEASE FOLLOW THE IMAGE AND CLICK ON THE IMAGE